Ventricular Fibrillation

  • Author: Sandeep K Goyal, MD; Chief Editor: Jeffrey N Rottman, MD  more...
Updated: Apr 29, 2014


Ventricular fibrillation (VF) is a life-threatening cardiac arrhythmia in which the coordinated contraction of the ventricular myocardium is replaced by high-frequency, disorganized excitation, resulting in failure of the heart to pump blood. VF is the most commonly identified arrhythmia in cardiac arrest patients. In the prehospital setting, 65-85% of patients in cardiac arrest have VF identified as the initial rhythm by emergency services personnel. (See Clinical Presentation and Workup.)

VF usually ends in death within minutes unless prompt corrective measures are instituted. The rate of survival in out-of-hospital cardiac arrest has increased with expansion of community-based emergency rescue systems, widespread use of automatic external defibrillators (AEDs), and increasing numbers of laypersons trained in bystander cardiopulmonary resuscitation (CPR). (See Prognosis, Treatment, and Medication.)

In hospital settings, VF is treated using Advanced Cardiac Life Support (ACLS) protocols. Long-term management may be accomplished with medical therapy or placement of an implantable cardioverter-defibrillator (ICD). Surgical correction of underlying disorders (eg, percutaneous coronary intervention, coronary artery bypass surgery) may also be indicated. (See Treatment and Medication.)

For related topics, see Ventricular Fibrillation in Emergency Medicine, Sudden Cardiac Death, and Pediatric Ventricular Fibrillation.

Patient education

For patient education information, see the Heart Health Center, Cholesterol Center, and Healthy Living Center, as well as Atrial Fibrillation (A Fib), Chest Pain, Heart Rhythm Disorders (Arrhythmias), Coronary Heart Disease, Heart Attack, CardiopulmonaryResuscitation (CPR), and Tetralogy of Fallot.



VF occurs in a variety of clinical situations but is most often associated with coronary artery disease (CAD). VF can result from acute myocardial infarction (MI) or ischemia or from myocardial scarring from an old infarct.[1] Ventricular tachycardia (VT) may degenerate into VF. Intracellular calcium accumulation, the action of free radicals, metabolic alterations, and autonomic modulation are important influences on the development of VF during ischemia.

Initiation of VF can occur in several ways. For example, if the myocardium is stimulated by a ventricular premature complex during the ascending limb of the T wave,[2] the impulse can propagate erratically through the variably refractory myocardial cells and establish reentrant patterns that result in chaotic ventricular depolarization. Consequently, coordinated myocardial contraction becomes disrupted.

The reentrant patterns break up into multiple smaller wavelets and the level of disorganization increases, with reentrant circuits producing high-frequency activation of cardiac muscle fibers. As the heart loses its ability to pump blood, myocardial ischemia worsens and a self-perpetuating vicious cycle ensues, leading to death if not corrected.

On the electrocardiogram (ECG), VF manifests as a chaotically irregular pattern. This pattern is coarse initially but becomes finer as ventricular disorganization increases. As the ECG waveform flattens, the likelihood of successful defibrillation decreases.[3]



Coronary artery disease (CAD) is the single most common etiologic factor predisposing patients to VF. In survivors of cardiac arrest, CAD with greater than 75% stenosis is observed in 40-86% of patients, depending on the age and sex of the population studied. In postmortem studies of people who have died from VF, extensive atherosclerosis is the most common pathologic finding.

In an autopsy study of 169 cases of coronary death, approximately 61% of patients had died suddenly of presumed VF, and another 15% of cases showed more than 75% stenosis in 3 or 4 vessels and similar severe lesions in at least 2 vessels.[4] No single coronary artery lesion is associated with an increased risk for VF.

Nevertheless, only approximately 20% of VF-related autopsies have shown evidence of a recent MI. A greater proportion of autopsies (40-70%) show evidence of a healed MI. Many of these hearts also reveal evidence of plaque fissuring, hemorrhage, and thrombosis.

The Coronary Artery Surgery Study (CASS) showed that surgically improving or restoring blood flow to the ischemic myocardium decreased the risk of VF, especially in patients with 3-vessel disease and heart failure, compared with medical treatment.[5] This finding suggests that transient acute ischemia is one of the major triggering events for sudden arrhythmic death.

The efficacy of beta-blocking agents in decreasing sudden death mortality rates, especially when administered to patients suffering from MI with VF, VT, and high-frequency premature ventricular contractions (PVCs), is thought to be partially caused by the ability of beta blockers to decrease ischemia. Beta blockers also increase the VF threshold in ischemic animals and decrease the rate of ventricular ectopy in patients with MI.

Reperfusion of ischemic myocardium with thrombolysis or angioplasty can induce transient electrical instability by several different mechanisms. One of these, coronary artery spasm, exposes the myocardium to both ischemia and reperfusion insults. Possible mechanisms of coronary vasospasm include autonomic nervous system factors, especially alpha-adrenergic activity; vagal activity; vessel susceptibility; and humoral factors, particularly those associated with platelet activation and aggregation.

Nonatherosclerotic coronary artery abnormalities are also associated with an increased incidence of sudden death. Such abnormalities include congenital lesions, embolism, arteritis, and mechanical abnormalities, such as coronary artery aneurysms.

When documentation of the antecedent rhythm is available, it often shows that rapid VT precedes VF. In patients with chronic ischemic heart disease, monomorphic VT arising from a reentrant focus is the most common precursor to VF. Other factors associated with increased risk of VF include frequent PVCs, particularly complex forms (such as multiform PVCs) and ones with short coupling intervals (R-on-T phenomenon).[6]

Even though many individuals have anatomic and functional cardiac substrates that predispose them to ventricular arrhythmias, only a small percentage develop VF. The interplay among regional ischemia, left ventricular (LV) dysfunction, and transient inciting events (eg, worsened ischemia, acidosis, hypoxemia, wall tension, drugs, metabolic disturbances) has been proposed to be the precipitator of VF.

An estimated 3-9% of cases of VT and VF occur in the absence of myocardial ischemia. Up to 1% of patients with out-of-hospital cardiac arrest have idiopathic VF with no discernable structural heart disease.[7] Up to 15% of patients younger than 40 years who experience VF have no underlying structural heart disease. In a 1993 study, Belhassen and Viskin noted that 4 out of 11 patients with a history of VF and no structural heart disease had histologic abnormalities on endomyocardial biopsy.[8]

Acute and chronic ischemic heart disease

Cardiac arrest attributable to ventricular arrhythmias may occur with acute ischemia or in the absence of an acute disturbance of coronary flow, due to scarring from a previous MI. An infarct scar can serve as the focus for reentrant ventricular tachyarrhythmias, which may occur shortly after the infarct or years later. Many studies support the relationship of symptomatic and asymptomatic ischemia as markers of myocardium at risk for arrhythmias.[9, 10]

Patients resuscitated from out-of-hospital cardiac arrest are at an increased risk for recurrent cardiac arrest and express an increased incidence of silent ST-segment depressions.[11] In animal models, experimentally induced myocardial ischemia has shown a strong relationship with the development of VF.

Nonischemic cardiomyopat hies

Patients with nonischemic cardiomyopathie s are the second largest group of patients who experience VF, accounting for approximately 10% of VF cases. Nonischemic myopathies, for the purposes of this article, can be divided into dilated, hypertrophic, and other, rarer forms.

Dilated cardiomyopathy

Dilated cardiomyopathy (DCM) is becoming increasingly more common, with an annual incidence of approximately 7.5 cases per 100,000 people. The prognosis after a VF event is very poor for these patients, with a 1-year mortality rate of 10-50%, depending on the New York Heart Association functional class; VF causes approximately 30-50% of these deaths.

DCM has varied etiologies, including idiopathic, viral, autoimmune, genetic, or environmental (eg, alcohol abuse). The predominant mechanism of sudden death in patients with DCM appears to be ventricular tachyarrhythmias, although bradyarrhythmias and electromechanical dissociation have also been observed, especially in patients with advanced LV dysfunction.[12] Extensive subendocardial fibrosis leading to ventricular dilation and subsequent generation of reentrant tachyarrhythmias is a proposed substrate for VF.

Multiple factors contribute to increased risk for VF in this population. The most important hemodynamic predictor is an increase in LV end-diastolic pressure and resulting increased wall tension. Other important factors are increased sympathetic tone, neurohumoral activation, and electrolyte abnormalities. Many drugs used in the treatment of heart failure, such as antiarrhythmics, inotropic agents, and diuretics, have proarrhythmic properties, which may provoke arrhythmias in some patients.

The genetic causes of DCM are myriad, with many genes, including those that encode actin, myosin, and troponin proteins, being implicated in its causation. Most familial DCMs are inherited in an autosomal dominant fashion, with mutations occurring in proteins that make up cardiac sarcomeres.

Interestingly, genes such as PSEN1 and PSEN2, which are responsible for early onset Alzheimer disease, have also been implicated in DCM. X-linked inheritance of DCM has been described in patients with mutations in the DMD (Duchenne muscular dystrophy) gene and the TAZ (Barth Syndrome) gene. Autosomal recessive inheritance has been described in mutations of the TNNI3 gene, which encodes the troponin I muscle protein.

Hypertrophic cardiomyopathy

Hypertrophic cardiomyopathy (HCM) is usually an autosomal dominant, incompletely penetrant genetic disorder resulting from a mutation in one of the many (>45) genes that encode proteins of the cardiac muscle sarcomere. Among the described genetic abnormalities are mutations in the genes encoding the beta-myosin heavy chains (MYH7), cardiac troponin T (TNNT2), myosin-binding protein C (MYBPC3), and cardiac troponin I.

Mutations in these 4 genes account for approximately 90% of HCM. The incidence of VF in this population is 2-4% per year in adults and 4-6% per year in children and adolescents. HCM is the most common cause of VF before age 30 years.

The mechanism of VF in HCM is not entirely understood. Ventricular arrhythmias in HCM are probably a result of a substrate of electrical instability and disorganized electrophysiologic transmission due to abnormal LV myocardial architecture. Intramural CAD leading to episodic myocardial ischemia and resulting necrosis and fibrosis has also been implicated as a potential substrate for VT/VF.[13]

The vast majority of young people who die of HCM are previously asymptomatic. Many experience VT/VF while at rest or with mild exertional activity; however, in a significant portion of these patients, the VF event occurs after vigorous exertion. The postexertional drop in blood pressure and shunting of blood to extracardiac tissues is postulated to worsen the outflow tract gradient and may therefore induce cardiac ischemia and malignant arrhythmias.

This downward cycle does not revert spontaneously, and it responds poorly to resuscitative efforts. HCM is the single greatest cause of VF in athletes and is therefore the major entity to screen for during the physical examination of an athlete.[14]

Arrhythmogenic right ventricular cardiomyopathy/dysplasia

ARVC/D is characterized by replacement of the RV wall with fibrofatty tissue. Involvement of the interventricular septum is unusual and involvement of the left ventricle is associated with poorer outcomes.[15]

The genetics of ARVC/D are extremely heterogeneous. To date, 8 genes (TGFB3, RYR2, DSP, PKP2, DSG2, TMEM43, and JUP) and 4 additional loci (14q12-q22, 2q32.1-32.3, 10p14-p12, and 10q22) have been implicated in the pathogenesis of this disorder, which is inherited in an autosomal dominant fashion with incomplete penetrance. Those 8 genes are thought to be responsible for approximately 42.5% of the total amount of ARVC/D.[16]

The majority of genetic mutations relate to desmosomal abnormalities. The desmosomes are proteins that are instrumental in cell-to-cell binding of myocytes.

Patients with ARVC/D, which is more prevalent in men than in women, may present with signs and symptoms of RV hypertrophy and dilatation, often with sustained monomorphic VT with left bundle-branch block morphology, with an axis usually between negative 90-100°. Less commonly, patients present with polymorphic VT. Atrial arrhythmias may be present in up to 25% of patients. The annual incidence rate of VF in patients with ARVC/D is approximately 2%.

Syncope and sudden death in ARVC/D are often associated with exercise. In many patients, sudden death—the incidence of which is highest in persons aged 30-50 years—is the first manifestation of the disease. Symptoms are rare in preadolescent children.

The most common ECG abnormality in ARVC/D is T-wave inversion in leads V1 -V3. Epsilon waves are seen in V1 or V2 as sharp spikes in the ST segment. In V1, a delayed-onset S wave (from nadir to baseline >60 msec) is a specific sign of ARVC/D (see the image below). In addition, PVCs with a left bundle-branch block pattern are common. Signal-averaged ECGs are abnormal in the majority of patients.

Epsilon wave on the electrocardiogram of a patient Epsilon wave on the electrocardiogram of a patient with arrhythmogenic right ventricular dysplasia.

ARVC/D differs from Uhl anomaly, a condition in which the RV wall is extremely thin because of apposition of endocardial and epicardial layers. Uhl anomaly usually manifests in the pediatric population, while arrhythmogenic RV cardiomyopathy usually manifests in adults.

The diagnosis can be confirmed with echocardiography or, preferably, with cardiac magnetic resonance imaging (MRI) studies. Voltage mapping of the right ventricle can be performed using a three-dimensional (3-D) mapping system and can show the presence of low-voltage areas (surrogate for scar or fatty infiltration) in the so-called triangle of dysplasia.

Since there is no gold standard for the diagnosis of ARVC/D, clinicians resort to the use of a variety of clinical abnormalities known as major and minor criteria. The diagnosis of ARVC/D is thought to be definite if the patient has any of the following[17, 18] :

  • At least 2 major criteria
  • 1 major and 2 minor criteria
  • 4 minor criteria

Valvular lesions

Aortic stenosis

Before the advent of surgical therapy for valvular heart disease, sudden cardiac death (SCD) was fairly common in patients with progressive aortic stenosis. Chizner et al followed 42 patients with isolated, unoperated aortic stenosis for over 5 years and found that symptomatic patients had a high mortality rate and that 56% of deaths occurred suddenly (within hours of the development of new symptoms). However, there were no deaths in asymptomatic patients.[19]

The mechanism of SCD in patients with uncorrected aortic stenosis is unclear, although malignant tachyarrhythmias and bradyarrhythmias have been documented. VF accounts for up to 20% of deaths after aortic valve replacement and remains the second most common cause of postoperative death in this population. The incidence of VF after aortic valve surgery is highest in the first 3 weeks after the procedure and then plateaus at 6-month follow-up.


Patients with chronic aortic insufficiency usually present with signs of chronic heart failure due to progressive LV dilatation and remodeling. As part of this process, reentrant or automatic ventricular foci may develop and cause symptomatic ventricular arrhythmias. After valve replacement, LV wall tension can be expected to lessen, and the risk of arrhythmia can be expected to decrease.

Mitral stenosis has become uncommon in the United States because of widespread use of antibiotics in primary streptococcal infections. SCD due to mitral stenosis is very rare.

The incidence of VF is low in patients with mitral valve prolapse (MVP). In clinically significant MVP, the risk of VF seems to rise along with the total mortality rate. The incidence of sudden death appears to vary with the presence of symptoms and the severity of mitral regurgitation. MVP has a 5-7% occurrence rate in the general population.[20]

Congenital structural heart disease

The causes of SCD are much more diverse in children than in adults. In reviewing 13 studies, involving 61 children and adolescents with VF, Driscoll and Edwards found that 50% of cases were due to HCM and that 25% resulted from anomalous origin of the left coronary artery. The remaining cases were due to aortic stenosis, cystic medial necrosis, and sinus node artery obstruction.[21]

Disease entities associated with VF in patients with known, previously recognized (including repaired) congenital heart disease include the following:

The predominant mechanism is ventricular arrhythmia. In patients with tetralogy of Fallot, up to 10% have VT after surgical correction of the anomaly, and the incidence of sudden death is 2-3%. In the Fontan procedure to correct a physiologic single ventricle, even atrial arrhythmias can cause severe hemodynamic compromise and arrhythmic death.

Patients who develop secondary pulmonary hypertension (Eisenmenger syndrome) despite attempted correction of the anatomic defects have a very poor prognosis. The terminal event may be bradycardia or VT progressing to VF.

Acquired childhood diseases associated with VF include Kawasaki syndrome, DCM, and myocarditis. Causes of VF in patients with previously unrecognized structural heart disease include HCM, congenital coronary artery abnormalities, and arrhythmogenic RV dysplasia.

Paroxysmal VF or short-coupled torsades

Paroxysmal familial VF can be caused by mutations in either the SCN5A or DPP6 gene. Mutations in the SCN5A gene are also associated with VF during MI.[24]

Idiopathic VF and VT

Idiopathic VF

Idiopathic VF is triggered by ventricular premature beats that may originate in the distal Purkinje conducting system, LV septum, anterior right ventricle, or RV outflow tract (RVOT). Early repolarization, or J wave (elevation at the junction of between the QRS complex and ST-segment), has been identified in patients with idiopathic VF and has been associated with mutations in a variety of ion channel genes.[25] Catheter ablation that targets triggers of ventricular premature beats can provide long-term freedom from recurrence of idiopathic VF.[26]

Idiopathic VT

RVOT tachycardia is responsible for 70-80% of idiopathic VTs but is a rare cause of VF. Idiopathic VT is generally associated with a benign prognosis.

RVOT tachycardia has a left bundle-branch block/inferior or right axis morphology on ECG. Idiopathic VTs that originate from the LV outflow tract (LVOT), aortic root, or LV septum are less common. However, with newer techniques of mapping and ablation, more PVC and VT foci are being mapped to the LVOT and aortic cusp area. Many patients with previous failed ablation for RVOT PVCs have undergone successful mapping and ablation in the LVOT or aortic cusp region.[27]

RVOT tachycardia is believed to be adrenergic-receptor mediated because exogenous and endogenous adenosine can terminate the arrhythmia. Maneuvers that increase endogenous acetylcholine may also terminate the arrhythmia.

Symptoms typical of RVOT tachycardia include palpitations, presyncope, or syncope, often occurring during or after exercise or emotional stress, but VT can also occur at rest. VF has been reported in patients with RVOT who have PVCs with short coupling intervals (in contrast to the long coupling intervals seen in patients with benign forms of RVOT tachycardia).[28]

Treatment of RVOT is based on the frequency and severity of symptoms. Beta blockers are first-line therapy. Patients with symptoms not relieved by medical therapy are best treated with radiofrequency catheter ablation. Successful ablation is reported in 83-100% of cases.

The next most common form of idiopathic VT arises from the fascicles of the left ventricle, notably the left posterior fascicle. These patients present with an ECG pattern during VT showing a right bundle-branch block and superior axis. The initial drug of choice is a calcium channel blocker. Catheter ablation is very effective. Other, less common forms of idiopathic VT originate from the LV papillary muscles or from the crux of the heart (the region at the base of the ventricle nearest the atrioventricular [AV] node).[29]

Pulmonary embolism

Pulmonary embolism is a frequent cause of sudden death in people at risk. Risk factors include previous personal or family history of deep venous thromboembolism, malignancy, hypercoagulable states, and recent mechanical trauma such as hip or knee surgery. Patients with pulmonary embolism can develop fatal ventricular arrhythmias (eg, VF) due to hemodynamic collapse and/or severe hypoxia.

Aortic dissection

Aortic dissection or aneurysmal rupture is a rather uncommon, but significant, cause of out-of-hospital cardiac arrest. Predisposing factors for aortic dissection include genetic deficiencies of collagen such as Marfan syndrome, Ehlers-Danlos syndrome, and aortic cystic medial necrosis. VF may be an observed finding at the scene of an aortic aneurysmal rupture.

Electronic control devices

Whether electronic control devices (eg, TASERs) can trigger VF has been studied in animal models, with contradictory results.[30] However, Zipes has reported human cases in which TASER stimulation apparently caused cardiac electrical capture and provoked cardiac arrest from VT/VF.[31]

Nonstructural abnormalities

These generally are a group of abnormalities in which patients have no apparent structural heart disease but have a primary electrophysiologic abnormality that predisposes them to VT or VF.[32] Some imaging techniques have detected abnormal sympathetic neural function in these patients. An ECG can provide clues to the diagnosis; consider a familial component to these conditions.

Causes of VF in patients with previously unrecognized, nonstructural heart disease include the following:

  • Long QT syndrome
  • Catecholaminergic polymorphic VT (CPVT)
  • Wolff-Parkinson-White (WPW) syndrome
  • Primary VT and VF
  • Primary pulmonary hypertension
  • Commotio cordis (traumatic blow to the chest wall causing VT/VF)
  • Brugada syndrome: It is possible that some patients with what is thought to be primary VF may have Brugada syndrome; VF in these patients usually has no preceding symptoms; the prognosis is unfavorable, and the recurrence rate is as high as 33%.

Congenital l ong QT syndrome

Congenital long QT syndrome results from abnormalities of channel proteins in the cardiac membrane. The most common forms involve loss of function of the potassium channel. Other forms may involve the sodium or calcium ion channels.

Prolongation of the QT interval is seen in the following genetic disorders:

  • Idiopathic long QT syndrome
  • Romano-Ward syndrome
  • Jervell and Lange-Nielsen syndrome (JLNS)
  • Andersen-Tawil syndrome
  • Timothy syndrome

Current cardiologic practice, however, is moving away from eponyms and instead toward denoting long QT syndrome by numbered type, based on identified underlying mutations. For example, long QT 1 is caused by mutations in the KCNQ1 gene; it is seen in Romano-Ward syndrome and JLNS.

The clinical course of long QT syndrome is quite variable, with some patients remaining asymptomatic and others developing torsade de pointes with syncope and sudden death. In 30% of cases, the syndrome is identified during an evaluation for syncope or aborted sudden death.

Patients at high risk for VF include those with deafness and first-degree relatives of patients with VF. VF in these patients is associated with emotional extremes, auditory auras or stimulation, and vigorous physical activity. Symptoms usually begin in childhood or adolescence. Schwartz et al have suggested diagnostic criteria for long QT syndrome in the absence of genetic testing (see Table 1, below).[33]

Table 1. Long QT syndrome diagnostic criteria (Open Table in a new window)

Category Criteria Points
Electrocardiographic Findings Corrected QT interval ≥480 ms 3
460-479 ms 2
450-459 ms (in males) 1
Torsade de pointes 2
T wave alternans 1
Notched T waves in three leads 1
Low heart rate for age (resting rate below second percentile 0.5
Clinical History Syncope With stress 2
Without stress 1
Congenital deafness 0.5
Family History Family members with definite long QT syndrome 1
Unexplained SCD before age 30 in immediate family members without definite long QT syndrome 0.5
Adapted from Schwartz PJ, Moss AJ, Vincent GM, Crampton RS. Diagnostic criteria for the long QT syndrome. An update. Circulation. 1993 Aug;88(2):782-4. PMID: 8339437[33]


≤1 point = low probability of long QT syndrome

>1 to 3 points = intermediate probability of long QT syndrome

≥3.5 points = high probability of long QT syndrome

The absence of a long QT interval on a single resting ECG does not exclude the diagnosis of LQTS. For example, it is possible that the patient may have incomplete penetrance that could be accentuated by drugs or metabolic conditions.

Treatment for LQTS includes beta blockers, high thoracic left sympathectomy, and ICDs.[34] For more information, see the Medscape Reference article Long QT Syndrome.

Idiopathic long QT syndrome

Idiopathic long QT syndrome is characterized clinically by a propensity to develop malignant ventricular arrhythmias. It is a rare familial disorder.

Romano-Ward syndrome

Romano-Ward syndrome describes a family of nonsyndromic long QT syndrome. It is characterized by prolongation of the QT interval, as well as T-wave abnormalities and polymorphic VT. Patients with this disease are predisposed to events of polymorphic VT, which can be self-limited, resulting in syncope. It can also transition into VF and can cause SCD.

Romano-Ward syndrome is inherited in an autosomal dominant fashion, with a penetrance of approximately 50%. Mutations in the KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 genes are known to be causative, and the 5 genes together are responsible for virtually 100% of cases of Romano-Ward syndrome.

Jervell and Lange-Nielsen syndrome

JLNS is characterized by congenital sensorineural deafness and a prolonged QT interval. Cardiac events tend to occur at a young age. JLNS is caused by mutations in the KCNQ1 or KCNE1 gene and has an autosomal recessive pattern of inheritance. Persons who are heterozygous for mutations in these genes may be asymptomatic or may manifest Romano-Ward syndrome, but they will have normal hearing.

Andersen-Tawil syndrome

Andersen-Tawil syndrome is chiefly characterized by the triad of periodic flaccid paralysis, prolonged QT interval, and dysmorphic facies. Patients with Andersen-Tawil syndrome have low-set ears, hypertelorism, micrognathia, syndactyly, and short stature.[23] They may also have mild learning disability.

This syndrome is caused by mutation in the KCNJ2 gene, which encodes the ik1 channel and is inherited in an autosomal dominant fashion. About half of affected patients have a de novo mutation.

Timothy syndrome

Timothy syndrome is characterized by the presence of a prolonged QT interval and cutaneous syndactyly. The syndactyly may be unilateral or bilateral and may be of variable severity. Other possible manifestations include cardiac defects, characteristic facial features, and neurologic problems.

Timothy syndrome is caused by mutation in the CACN1C gene, which encodes the α subunit of the Ca++ channel. It is usually the result of a de novo mutation but is transmitted in an autosomal dominant fashion.[35]

Acquired long QT syndrome

A number of antiarrhythmics (especially class Ia and class III) and other medications, electrolyte abnormalities, cerebrovascular diseases, and altered nutritional states cause QT prolongation and put patients at risk for torsade de pointes. This usually occurs when QT prolongation is associated with a slow heart rate and hypokalemia.

The QT interval is prolonged in up 32% of patients with intracranial hemorrhage (especially subarachnoid hemorrhage). Stroke or intracranial trauma can also result in QT interval prolongation. Lesions in the hypothalamus are thought to lead to this phenomenon. In rare cases, QT prolongation from subarachnoid hemorrhage results in torsades de pointes.

Electrolyte abnormalities that cause acquired long QT syndrome include hypokalemia, hypomagnesemia, and hypocalcemia. Such abnormalities may result from nutritional deficiencies associated with modified starvation diets and severe weight-loss programs. Altered autonomic status (eg, diabetic neuropathy) can cause long QT syndrome. Rarely, hypothyroidism may result in QT interval prolongation.

Class Ia antiarrhythmic drugs that cause acquired long QT syndrome include quinidine, disopyramide, and procainamide. Class III antiarrhythmic drugs that cause acquired long QT syndrome include the following:

  • Sotalol
  • Amiodarone
  • Dofetilide
  • Ibutilide

Other drugs that can cause acquired long QT syndrome include the following:

  • Tricyclic and tetracyclic antidepressants
  • Phenothiazines
  • Haloperidol
  • Antibiotics (eg, intravenous erythromycin, sulfamethoxazole/trimethoprim)
  • Chemotherapeutics (eg, pentamidine, anthracycline)
  • Serotonin antagonists (eg, ketanserin, zimeldine)
  • Organophosphorus insecticides

A comprehensive list of drugs that can prolong the QT interval is available at

Catecholaminergic polymorphic VT

CPVT can be triggered by emotional stress or exercise and can also be induced by catecholamine administration. Patients may present with syncope, or SCD may occur if polymorphic VT degrades into VF. Results of physical examination or resting ECG are usually normal.

CPVT may be caused by mutations in the RYR2 gene (autosomal dominant) or the CASQ2 gene (autosomal recessive).[36] An additional locus has been mapped to chromosome 7p22-p14. Symptoms, including sudden death, usually appear in childhood or among young adults. Most cases of CPVT respond to beta-blocker therapy. Flecainide has also been found to be beneficial.[37] Invasive treatments include left cervical sympathectomy, implantable cardioverter-defibrillator (ICD) placement, or both.

Wolff-Parkinson-White syndrome

WPW syndrome is a rare cause of sudden death. The presence of multiple accessory pathways, posteroseptal accessory pathways, and a preexcited R-R interval of less than 220 msec during atrial fibrillation is associated with higher risk for VF.[38]

Most cases of VF in patients with WPW syndrome are induced by atrial fibrillation with a rapid ventricular response over the accessory pathway (see the image below). In a study by Klein et al of 31 patients with VF and WPW syndrome, a history of atrial fibrillation or reciprocating tachycardia was an important predisposing factor.[38]

Ventricular fibrillation appeared during rapid atr Ventricular fibrillation appeared during rapid atrial fibrillation in a patient with Wolff-Parkinson-White syndrome.

Mutation in the PRKAG2 gene can cause WPW. The syndrome is likely inherited in an autosomal dominant manner with reduced penetrance. It is not known what percentage of patients with WPW has a mutation in this gene.

Treatment of WPW should be individualized for each patient and is based in part on risk assessment. Risk assessment can be noninvasive, but symptomatic patients and those with sustained preexcitation during a treadmill exercise stress test require invasive risk stratification via an electrophysiologic (EP) study.

In high-risk patients (ie, those with multiple pathways, history of sustained reciprocating tachycardia, or short preexcited RR interval during atrial fibrillation [< 220 msec]), preventing the occurrence of arrhythmias is possible by interrupting the anomalous pathway with catheter ablation. Autonomic tone can alter conduction over a bypass tract, and complete assessment of the “shortest preexcited RR interval” includes assessment with the infusion of isoproterenol.[39]

Atrial fibrillation in patients with WPW can be associated with rapid ventricular rates due to rapid conduction over an accessory pathway with a short refractory period. Pure atrioventricular (AV) nodal blocking drugs (beta blockers, calcium channel blockers) should not be used alone, as they will block the AV node without affecting the accessory pathway; this can increase preferential conduction over the pathway, leading to faster ventricular rates.

Drugs such as ibutilide, procainamide, and amiodarone are useful, as they prolong the anterograde refractory period of the pathway and hence slow the conduction over the pathway. Electrical cardioversion is the preferred treatment for patients with hemodynamic instability.

Brugada syndrome

Brugada syndrome was first described in 1992 by Brugada and Brugada.[40] It is characterized by a specific ECG pattern of right bundle-branch block and ST-segment elevation in leads V1 and V2 without any structural abnormality of the heart.[41]

Brugada syndrome can be caused by mutations in many genes. The principal gene associated with the syndrome is SCN5A, nearly 300 mutations of which have been described.[42] Other genes known to cause the syndrome include GPD1L, CACNA1C, CACNB2, SCN1B, KCNE3, SCN3B, and HCN4. Brugada syndrome is inherited in an autosomal dominant fashion.

Patients with this syndrome are at high risk for VF. In equivocal cases, intravenous (IV) procainamide will augment the Brugada ECG pattern.[43] In an early follow-up study of 63 patients with the syndrome, asymptomatic patients were found to have the same risk for arrhythmia as patients who had an episode of aborted sudden death.[44]

In this study, treatment with amiodarone, beta blockers, or both did not confer a lesser risk of death, whereas the patients with ICDs had no deaths due to arrhythmia. Thus, placement of an ICD is considered the treatment of choice for Brugada syndrome.[44]

Larger, subsequent studies have emphasized a much lower risk for SCD in asymptomatic patients with an episodic Brugada pattern.[45] Other therapeutic options include IV isoproterenol for management of VF storm and oral quinidine as outpatient therapy for avoiding ICD shocks.[46] Other important aspects of therapy include prompt treatment of fever and avoidance of drugs that cause sodium channel blockade.



Many VF episodes are unwitnessed, making it difficult to assess an exact incidence. Of the approximately 300,000 cases of SCD that occur each year in the United States, up to a third are attributed to VF.[47] This represents an incidence of 0.08-0.16% per year in the adult population, accounting for more deaths than from lung cancer, breast cancer, or acquired immunodeficiency syndrome (AIDS). In the pediatric and adolescent age groups, VF occurs with an annual incidence of 1.3-8.5 cases per 100,000 persons, accounting for approximately 5% of all deaths in this group.

VF is often the first expression of CAD and is responsible for approximately 50% of deaths from CAD. VF often occurs within the first hour after the onset of an acute MI or acute coronary syndrome.

In several population-based studies, the incidence of out-of-hospital cardiac arrest in the United States has been noted as declining in the past 2 decades, but the proportion of sudden deaths from VF in patients with CAD has not changed. A high incidence of VF occurs among certain population subgroups (eg, patients with chronic heart failure with ejection fraction < 30%, patients in the convalescent phase after MI, patients who survived cardiac arrest); however, only a small percentage of total VF events occur in these patients.

Survivors of a major cardiovascular event have an increased risk for VF in the first 6-24 months after the event. Up to 30% of survivors of cardiac arrest may experience recurrent VF in the first year afterward.

The frequency of VF in other industrialized Western nations is similar to that in the United States.[48] The incidence of VF in other countries varies as a reflection of CAD prevalence in those populations. The trend toward increasing frequency of VF events in developing nations is thought to reflect a change in dietary and lifestyle habits.

Cardiovascular events, including SCD from VF (but not asystole), most frequently occur in the morning and may be related to increased platelet aggregability. A spike in the number of SCDs also appears to occur during the winter months.

Race-, sex-, and age-related demographics

Most data are inconclusive regarding racial differences and the incidence of VF. Some studies suggest that a greater proportion of coronary deaths have been sudden in blacks than in whites.[49] In a report by Gillum on SCD from 1980-1985, the percentage of CAD deaths occurring out of the hospital and in emergency departments was higher in blacks than in whites.[50]

The incidence of VF is higher in men than in women (3:1).[51] This ratio generally reflects the higher incidence of CAD in men. Although the mechanism of MI tends to differ by sex—coronary plaque rupture in men and plaque erosion in women—it is unclear whether this difference accounts for the male predominance of VF.

The incidence of VF parallels the prevalence of CAD, with the peak rate of VF occurring in people aged 45-75 years. However, the proportion of sudden deaths from CAD decreases with age. In the Framingham Heart Study, the proportion of sudden CAD deaths was 62% in men aged 45-54 years, decreasing to 58% in men aged 55-64 years and to 42% in men aged 65-74 years.[52] According to Kuller, 31% of deaths are sudden in people aged 20-29 years.[53]



The chances of survival from an index VF event depend on bystander cardiopulmonary resuscitation (CPR), rapid availability or arrival of personnel and apparatus for defibrillation and advanced life support, and transport to a hospital. Although patients with nontraumatic cardiac arrest are more likely to be successfully resuscitated from VF than from any other arrhythmia, success is highly time dependent. The probability of success generally declines at a rate of 2-10% per minute.

Early defibrillation often makes the difference between long-term disability and functional recovery. Placement of automatic external defibrillators (AEDs) throughout communities and training of the public in their use has the potential to improve outcomes from sudden cardiac death (SCD).[54]

In patients presenting to an emergency department (ED) after a witnessed episode of VF, the prognosis for morbidity and mortality can be determined by calculating the cardiac arrest score, developed by Thompson and McCullough.[55] This score is based on systolic blood pressure, time from loss of consciousness to return of spontaneous circulation, and neurologic responsiveness. (See Clinical Presentation for details.)

Even under ideal circumstances, however, only an estimated 20% of persons who have out-of-hospital cardiac arrest survive to hospital discharge. In a study of out-of-hospital cardiac arrest survival in New York City, only 1.4% of patients survived to hospital discharge.[56] On the other hand, studies in suburban and rural areas have indicated survival rates of up to 35%.[57]

Routine coronary angiography, with percutaneous coronary intervention (PCI), if indicated, along with mild therapeutic hypothermia (core temperature of 32-34°C for 24 hours), may favorably alter the prognosis of resuscitated patients with stable hemodynamics after out-of-hospital cardiac arrest.[58] In a retrospective study of cardiac arrest survivors, 65.6% of patients who underwent early coronary angiography survived to hospital discharge, compared with 48.6% of those who did not receive coronary angiography.[59]

A major adverse outcome from VF episodes is anoxic encephalopathy, which occurs in 30-80% of patients. A study conducted in Minnesota on all adult survivors of out-of-hospital VF-related cardiac arrest from 1990-2008 found that long-term survivors had long-term memory deficits.[60]

Contributor Information and Disclosures

Sandeep K Goyal, MD Clinical Fellow in Cardiac Electrophysiology, Division of Cardiovascular Medicine, Vanderbilt University Medical Center

Sandeep K Goyal, MD is a member of the following medical societies: American College of Cardiology, American Heart Association, American Medical Association, Heart Rhythm Society

Disclosure: Nothing to disclose.


Jeffrey N Rottman, MD Professor of Medicine, Department of Medicine, Division of Cardiovascular Medicine, University of Maryland School of Medicine; Cardiologist/Electrophysiologist, University of Maryland Medical System and VA Maryland Health Care System

Jeffrey N Rottman, MD is a member of the following medical societies: American Heart Association, Heart Rhythm Society

Disclosure: Nothing to disclose.

Chief Editor

Jeffrey N Rottman, MD Professor of Medicine, Department of Medicine, Division of Cardiovascular Medicine, University of Maryland School of Medicine; Cardiologist/Electrophysiologist, University of Maryland Medical System and VA Maryland Health Care System

Jeffrey N Rottman, MD is a member of the following medical societies: American Heart Association, Heart Rhythm Society

Disclosure: Nothing to disclose.


Robert E Fowles, MD Clinical Professor of Medicine, University of Utah College of Medicine; Consulting Staff, Intermountain Medical Center and LDS Hospital; Director and Consulting Staff, Department of Cardiology, Salt Lake Clinic

Robert E Fowles, MD is a member of the following medical societies: American College of Cardiology, American College of Physicians, and American Heart Association

Disclosure: Nothing to disclose.

Brian Olshansky, MD Professor of Medicine, Department of Internal Medicine, University of Iowa College of Medicine

Brian Olshansky, MD is a member of the following medical societies: American Autonomic Society, American College of Cardiology, American College of Chest Physicians, American College of Physicians, American College of Sports Medicine, American Federation for Clinical Research, American Heart Association, Cardiac Electrophysiology Society, Heart Rhythm Society, and New York Academy of Sciences

Disclosure: Guidant/Boston Scientific Honoraria Speaking and teaching; Medtronic Honoraria Speaking and teaching; Guidant/Boston Scientific Consulting fee Consulting; Novartis Honoraria Speaking and teaching; Novartis Consulting fee Consulting

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

  1. Warnes CA, Roberts WC. Sudden coronary death: relation of amount and distribution of coronary narrowing at necropsy to previous symptoms of myocardial ischemia, left ventricular scarring and heart weight. Am J Cardiol. 1984 Jul 1. 54(1):65-73. [Medline].

  2. Anthony R, Daubert JP, Zareba W, Andrews ML, McNitt S, Levine E. Mechanisms of ventricular fibrillation initiation in MADIT II patients with implantable cardioverter defibrillators. Pacing Clin Electrophysiol. 2008 Feb. 31(2):144-50. [Medline].

  3. Menegazzi JJ, Callaway CW, Sherman LD, Hostler DP, Wang HE, Fertig KC, et al. Ventricular fibrillation scaling exponent can guide timing of defibrillation and other therapies. Circulation. 2004 Feb 24. 109(7):926-31. [Medline].

  4. Rissanen V. Coronary atherosclerosis in cases of coronary death as compared with that occurring in the populatiom. A study of a medico-legal autopsy series of coronary deaths and violent deaths. Ann Clin Res. 1975 Dec. 7(6):412-25. [Medline].

  5. Holmes DR Jr, Davis K, Gersh BJ, et al. Risk factor profiles of patients with sudden cardiac death and death from other cardiac causes: a report from the Coronary Artery Surgery Study (CASS). J Am Coll Cardiol. 1989 Mar 1. 13(3):524-30. [Medline].

  6. Bigger JT Jr, Fleiss JL, Kleiger R, et al. The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction. Circulation. 1984 Feb. 69(2):250-8. [Medline].

  7. Tung RT, Shen WK, Hammill SC, Gersh BJ. Idiopathic ventricular fibrillation in out-of-hospital cardiac arrest survivors. Pacing Clin Electrophysiol. 1994 Aug. 17(8):1405-12. [Medline].

  8. Belhassen B, Viskin S. Idiopathic ventricular tachycardia and fibrillation. J Cardiovasc Electrophysiol. 1993 Jun. 4(3):356-68. [Medline].

  9. Bikkina M, Larson MG, Levy D. Prognostic implications of asymptomatic ventricular arrhythmias: the Framingham Heart Study. Ann Intern Med. 1992 Dec 15. 117(12):990-6. [Medline].

  10. Sharma B, Asinger R, Francis GS, et al. Demonstration of exercise-induced painless myocardial ischemia in survivors of out-of-hospital ventricular fibrillation. Am J Cardiol. 1987 Apr 1. 59(8):740-5. [Medline].

  11. Cobb LA, Baum RS, Alvarez H 3rd, Schaffer WA. Resuscitation from out-of-hospital ventricular fibrillation: 4 years follow-up. Circulation. 1975 Dec. 52(6 Suppl):III223-35. [Medline].

  12. Larsen L, Markham J, Haffajee CI. Sudden death in idiopathic dilated cardiomyopathy: role of ventricular arrhythmias. Pacing Clin Electrophysiol. 1993 May. 16(5 Pt 1):1051-9. [Medline].

  13. Maron BJ, Wolfson JK, Epstein SE, Roberts WC. Intramural ("small vessel") coronary artery disease in hypertrophic cardiomyopathy. J Am Coll Cardiol. 1986 Sep. 8(3):545-57. [Medline].

  14. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl J Med. 2002 Feb 21. 346(8):549-56. [Medline].

  15. Corrado D, Basso C, Thiene G, et al. Spectrum of clinicopathologic manifestations of arrhythmogenic right ventricular cardiomyopathy/dysplasia: a multicenter study. J Am Coll Cardiol. 1997 Nov 15. 30(6):1512-20. [Medline].

  16. Pilichou K, Nava A, Basso C, Beffagna G, Bauce B, Lorenzon A, et al. Mutations in desmoglein-2 gene are associated with arrhythmogenic right ventricular cardiomyopathy. Circulation. 2006 Mar 7. 113(9):1171-9. [Medline].

  17. McKenna WJ, Beiras AC, Lado MP. The cardiomyopathies. Br Heart J. 1994 Dec. 72(6 Suppl):S1. [Medline]. [Full Text].

  18. [Guideline] Marcus FI, McKenna WJ, Sherrill D, Basso C, Bauce B, Bluemke DA, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Circulation. 2010 Apr 6. 121(13):1533-41. [Medline]. [Full Text].

  19. Chizner MA, Pearle DL, deLeon AC Jr. The natural history of aortic stenosis in adults. Am Heart J. 1980 Apr. 99(4):419-24. [Medline].

  20. Kligfield P, Levy D, Devereux RB. Arrhythmias and sudden death in mitral valve prolapse. Am Heart J. 1987 May. 113(5):1298-307. [Medline].

  21. Driscoll DJ, Edwards WD. Sudden unexpected death in children and adolescents. J Am Coll Cardiol. 1985 Jun. 5(6 Suppl):118B-121B. [Medline].

  22. Myerburg RJ, Mitrani R, Interian A Jr, Castellanos A. Identification of risk of cardiac arrest and sudden cardiac death in athletes. Estes NA, Salem DN, Wang PJ, eds. Sudden Cardiac Death in the Athlete. Armonk, NY: Futura Publishing; 1996. 25.

  23. Young D, Mark H. Fate of the patient with the Eisenmenger syndrome. Am J Cardiol. 1971 Dec. 28(6):658-69. [Medline].

  24. Bezzina CR, Pazoki R, Bardai A, Marsman RF, de Jong JS, Blom MT, et al. Genome-wide association study identifies a susceptibility locus at 21q21 for ventricular fibrillation in acute myocardial infarction. Nat Genet. 2010 Aug. 42(8):688-91. [Medline].

  25. Watanabe H, Nogami A, Ohkubo K, Kawata H, Hayashi Y, Ishikawa T, et al. Electrocardiographic characteristics and SCN5A mutations in idiopathic ventricular fibrillation associated with early repolarization. Circ Arrhythm Electrophysiol. 2011 Dec. 4(6):874-81. [Medline].

  26. Knecht S, Sacher F, Wright M, Hocini M, Nogami A, Arentz T, et al. Long-term follow-up of idiopathic ventricular fibrillation ablation: a multicenter study. J Am Coll Cardiol. 2009 Aug 4. 54(6):522-8. [Medline].

  27. Yokokawa M, Good E, Crawford T, Chugh A, Pelosi F Jr, Latchamsetty R, et al. Reasons for failed ablation for idiopathic right ventricular outflow tract-like ventricular arrhythmias. Heart Rhythm. 2013 Aug. 10(8):1101-8. [Medline].

  28. Viskin S, Rosso R, Rogowski O, Belhassen B. The "short-coupled" variant of right ventricular outflow ventricular tachycardia: a not-so-benign form of benign ventricular tachycardia?. J Cardiovasc Electrophysiol. 2005 Aug. 16(8):912-6. [Medline].

  29. P Doppalapudi H. Idiopathic focal epicardial ventricular tachycardia originating from the crux of the heart. Heart Rhythm. 2009 Jan. 6(1):44-50.

  30. Nanthakumar K, Massé S, Umapathy K, Dorian P, Sevaptsidis E, Waxman M. Cardiac stimulation with high voltage discharge from stun guns. CMAJ. 2008 May 20. 178(11):1451-7. [Medline]. [Full Text].

  31. Zipes DP. Sudden cardiac arrest and death following application of shocks from a TASER electronic control device. Circulation. 2012 May 22. 125(20):2417-22. [Medline].

  32. Wever EF, Hauer RN, Oomen A, et al. Unfavorable outcome in patients with primary electrical disease who survived an episode of ventricular fibrillation. Circulation. 1993 Sep. 88(3):1021-9. [Medline].

  33. Schwartz PJ, Moss AJ, Vincent GM, Crampton RS. Diagnostic criteria for the long QT syndrome. An update. Circulation. 1993 Aug. 88(2):782-4. [Medline].

  34. Moss AJ. Clinical management of patients with the long QT syndrome: drugs, devices, and gene-specific therapy. Pacing Clin Electrophysiol. 1997 Aug. 20(8 Pt 2):2058-60. [Medline].

  35. Splawski I, Timothy KW, Sharpe LM, Decher N, Kumar P, Bloise R, et al. Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell. 2004 Oct 1. 119(1):19-31. [Medline].

  36. Priori SG, Napolitano C, Memmi M, Colombi B, Drago F, Gasparini M, et al. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation. 2002 Jul 2. 106(1):69-74. [Medline].

  37. Watanabe H, Chopra N, Laver D, Hwang HS, Davies SS, Roach DE, et al. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med. 2009 Apr. 15(4):380-3. [Medline]. [Full Text].

  38. Klein GJ, Bashore TM, Sellers TD, et al. Ventricular fibrillation in the Wolff-Parkinson-White syndrome. N Engl J Med. 1979 Nov 15. 301(20):1080-5. [Medline].

  39. Moore JP, Kannankeril PJ, Fish FA. Isoproterenol administration during general anesthesia for the evaluation of children with ventricular preexcitation. Circ Arrhythm Electrophysiol. 2011 Feb. 4(1):73-8. [Medline].

  40. Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. J Am Coll Cardiol. 1992 Nov 15. 20(6):1391-6. [Medline].

  41. Gussak I, Antzelevitch C, Bjerregaard P, et al. The Brugada syndrome: clinical, electrophysiologic and genetic aspects. J Am Coll Cardiol. 1999 Jan. 33(1):5-15. [Medline].

  42. Kapplinger JD, Tester DJ, Alders M, Benito B, Berthet M, Brugada J, et al. An international compendium of mutations in the SCN5A-encoded cardiac sodium channel in patients referred for Brugada syndrome genetic testing. Heart Rhythm. 2010 Jan. 7(1):33-46. [Medline]. [Full Text].

  43. Wilde AA, Antzelevitch C, Borggrefe M, Brugada J, Brugada R, Brugada P, et al. Proposed diagnostic criteria for the Brugada syndrome. Eur Heart J. 2002 Nov. 23(21):1648-54. [Medline].

  44. Brugada J, Brugada R, Brugada P. Right bundle-branch block and ST-segment elevation in leads V1 through V3: a marker for sudden death in patients without demonstrable structural heart disease. Circulation. 1998 Feb 10. 97(5):457-60. [Medline].

  45. Priori SG, Gasparini M, Napolitano C, Della Bella P, Ottonelli AG, Sassone B, et al. Risk stratification in Brugada syndrome: results of the PRELUDE (PRogrammed ELectrical stimUlation preDictive valuE) registry. J Am Coll Cardiol. 2012 Jan 3. 59(1):37-45. [Medline].

  46. Belhassen B, Glick A, Viskin S. Efficacy of quinidine in high-risk patients with Brugada syndrome. Circulation. 2004 Sep 28. 110(13):1731-7. [Medline].

  47. McNally B, Robb R, Mehta M, Vellano K, Valderrama AL, Yoon PW, et al. Out-of-hospital cardiac arrest surveillance --- Cardiac Arrest Registry to Enhance Survival (CARES), United States, October 1, 2005--December 31, 2010. MMWR Surveill Summ. 2011 Jul 29. 60(8):1-19. [Medline].

  48. Holmberg M, Holmberg S, Herlitz J. The problem of out-of-hospital cardiac-arrest prevalence of sudden death in Europe today. Am J Cardiol. 1999 Mar 11. 83(5B):88D-90D. [Medline].

  49. Becker LB, Han BH, Meyer PM, et al. Racial differences in the incidence of cardiac arrest and subsequent survival. The CPR Chicago Project. N Engl J Med. 1993 Aug 26. 329(9):600-6. [Medline].

  50. Gillum RF. Sudden cardiac death in Hispanic Americans and African Americans. Am J Public Health. 1997 Sep. 87(9):1461-6. [Medline].

  51. Schatzkin A, Cupples LA, Heeren T, et al. Sudden death in the Framingham Heart Study. Differences in incidence and risk factors by sex and coronary disease status. Am J Epidemiol. 1984 Dec. 120(6):888-99. [Medline].

  52. Gordon T, Kannel WB. Premature mortality from coronary heart disease. The Framingham study. JAMA. 1971 Mar 8. 215(10):1617-25. [Medline].

  53. Kuller LH. Sudden death--definition and epidemiologic considerations. Prog Cardiovasc Dis. 1980 Jul-Aug. 23(1):1-12. [Medline].

  54. Winkle RA. The effectiveness and cost effectiveness of public-access defibrillation. Clin Cardiol. 2010 Jul. 33(7):396-9. [Medline].

  55. McCullough PA, Thompson RJ, Tobin KJ. Validation of a decision support tool for the evaluation of cardiac arrest victims. Clin Cardiol. 1998 Mar. 21(3):195-200. [Medline].

  56. Lombardi G, Gallagher J, Gennis P. Outcome of out-of-hospital cardiac arrest in New York City. The Pre- Hospital Arrest Survival Evaluation (PHASE) Study. JAMA. 1994 Mar 2. 271(9):678-83. [Medline].

  57. Waalewijn RA, de Vos R, Koster RW. Out-of-hospital cardiac arrests in Amsterdam and its surrounding areas: results from the Amsterdam resuscitation study (ARREST) in 'Utstein' style. Resuscitation. 1998 Sep. 38(3):157-67. [Medline].

  58. Cronier P, Vignon P, Bouferrache K, et al. Impact of routine percutaneous coronary intervention after out-of-hospital cardiac arrest due to ventricular fibrillation. Crit Care. 2011 May 11. 15(3):R122. [Medline].

  59. Hollenbeck RD, McPherson JA, Mooney MR, Unger BT, Patel NC, McMullan PW Jr, et al. Early cardiac catheterization is associated with improved survival in comatose survivors of cardiac arrest without STEMI. Resuscitation. 2014 Jan. 85(1):88-95. [Medline].

  60. Mateen FJ, Josephs KA, Trenerry MR, et al. Long-term cognitive outcomes following out-of-hospital cardiac arrest: A population-based study. Neurology. 2011 Sep 14. [Medline].

  61. Surawicz B. Ventricular fibrillation. J Am Coll Cardiol. 1985 Jun. 5(6 Suppl):43B-54B. [Medline].

  62. Thompson RJ, McCullough PA, Kahn JK. Prediction of death and neurologic outcome in the emergency department in out-of-hospital cardiac arrest survivors. Am J Cardiol. 1998 Jan 1. 81(1):17-21. [Medline].

  63. McCullough PA, Prakash R, Tobin KJ. Application of a cardiac arrest score in patients with sudden death and ST segment elevation for triage to angiography and intervention. J Interv Cardiol. 2002 Aug. 15(4):257-61. [Medline].

  64. Turitto G, Ahuja RK, Caref EB, el-Sherif N. Risk stratification for arrhythmic events in patients with nonischemic dilated cardiomyopathy and nonsustained ventricular tachycardia: role of programmed ventricular stimulation and the signal-averaged electrocardiogram. J Am Coll Cardiol. 1994 Nov 15. 24(6):1523-8. [Medline].

  65. Brugada P, Geelen P. Some electrocardiographic patterns predicting sudden cardiac death that every doctor should recognize. Acta Cardiol. 1997. 52(6):473-84. [Medline].

  66. Gibson RS, Watson DD, Craddock GB. Prediction of cardiac events after uncomplicated myocardial infarction: a prospective study comparing predischarge exercise thallium-201 scintigraphy and coronary angiography. Circulation. 1983 Aug. 68(2):321-36. [Medline].

  67. Risk stratification and survival after myocardial infarction. N Engl J Med. 1983 Aug 11. 309(6):331-6. [Medline].

  68. Zheutlin TA, Steinman RT, Mattioni TA, Kehoe RF. Long-term arrhythmic outcome in survivors of ventricular fibrillation with absence of inducible ventricular tachycardia. Am J Cardiol. 1988 Dec 1. 62(17):1213-7. [Medline].

  69. Buxton AE, Waxman HL, Marchlinski FE, Untereker WJ, Waspe LE, Josephson ME. Role of triple extrastimuli during electrophysiologic study of patients with documented sustained ventricular tachyarrhythmias. Circulation. 1984 Mar. 69(3):532-40. [Medline].

  70. Iesaka Y, Nogami A, Aonuma K, Nitta J, Chun YH, Fujiwara H, et al. Prognostic significance of sustained monomorphic ventricular tachycardia induced by programmed ventricular stimulation using up to triple extrastimuli in survivors of acute myocardial infarction. Am J Cardiol. 1990 May 1. 65(16):1057-63. [Medline].

  71. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med. 1999 Dec 16. 341(25):1882-90. [Medline].

  72. Morrison LJ, Deakin CD, Morley PT, Callaway CW, Kerber RE, Kronick SL, et al. Part 8: advanced life support: 2010 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. Circulation. 2010 Oct 19. 122(16 Suppl 2):S345-421. [Medline].

  73. Hazinski MF, Nolan JP, Billi JE et al. Part 1: executive summary: 2010 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. Circulation. 2010 Oct 19. 122(16 Suppl 2):S250-75. [Medline].

  74. White RD, Hankins DG, Bugliosi TF. Seven years'' experience with early defibrillation by police and paramedics in an emergency medical services system. Resuscitation. 1998 Dec. 39(3):145-51. [Medline].

  75. Domanski MJ, Sakseena S, Epstein AE, et al. Relative effectiveness of the implantable cardioverter-defibrillator and antiarrhythmic drugs in patients with varying degrees of left ventricular dysfunction who have survived malignant ventricular arrhythmias. AVID Investigators. Antiarrhythmics Ver. J Am Coll Cardiol. 1999 Oct. 34(4):1090-5. [Medline].

  76. Lessmeier TJ, Lehmann MH, Steinman RT, et al. Outcome with implantable cardioverter-defibrillator therapy for survivors of ventricular fibrillation secondary to idiopathic dilated cardiomyopathy or coronary artery disease without myocardial infarction. Am J Cardiol. 1993 Oct 15. 72(12):911-5. [Medline].

  77. Meissner MD, Lehmann MH, Steinman RT, et al. Ventricular fibrillation in patients without significant structural heart disease: a multicenter experience with implantable cardioverter- defibrillator therapy. J Am Coll Cardiol. 1993 May. 21(6):1406-12. [Medline].

  78. Maron BJ, Shen WK, Link MS, et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med. 2000 Feb 10. 342(6):365-73. [Medline].

  79. Rea TD, Fahrenbruch C, Culley L, Donohoe RT, Hambly C, Innes J, et al. CPR with chest compression alone or with rescue breathing. N Engl J Med. 2010 Jul 29. 363(5):423-33. [Medline].

  80. Iwami T, Kitamura T, Kawamura T, Mitamura H, Nagao K, Takayama M, et al. Chest compression-only cardiopulmonary resuscitation for out-of-hospital cardiac arrest with public-access defibrillation: a nationwide cohort study. Circulation. 2012 Dec 11. 126(24):2844-51. [Medline].

  81. Ewy GA, Sanders AB. Alternative approach to improving survival of patients with out-of-hospital primary cardiac arrest. J Am Coll Cardiol. 2013 Jan 15. 61(2):113-8. [Medline].

  82. Hassan TB, Jagger C, Barnett DB. A randomised trial to investigate the efficacy of magnesium sulphate for refractory ventricular fibrillation. Emerg Med J. 2002 Jan. 19(1):57-62. [Medline]. [Full Text].

  83. Bernard SA, Gray TW, Buist MD, Jones BM, Silvester W, Gutteridge G, et al. Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. N Engl J Med. 2002 Feb 21. 346(8):557-63. [Medline].

  84. Nielsen N, Wetterslev J, Cronberg T, Erlinge D, Gasche Y, Hassager C, et al. Targeted temperature management at 33°C versus 36°C after cardiac arrest. N Engl J Med. 2013 Dec 5. 369(23):2197-206. [Medline].

  85. [Guideline] Epstein AE, DiMarco JP, Ellenbogen KA, Estes NA 3rd, Freedman RA, Gettes LS, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation. 2008 May 27. 117(21):e350-408. [Medline].

  86. [Guideline] Tracy CM, Epstein AE, Darbar D, Dimarco JP, Dunbar SB, Estes NA 3rd, et al. 2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2012 Oct 2. 60(14):1297-313. [Medline]. [Full Text].

  87. Cappato R. Secondary prevention of sudden death: the Dutch Study, the Antiarrhythmics Versus Implantable Defibrillator Trial, the Cardiac Arrest Study Hamburg, and the Canadian Implantable Defibrillator Study. Am J Cardiol. 1999 Mar 11. 83(5B):68D-73D. [Medline].

  88. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med. 1997 Nov 27. 337(22):1576-83. [Medline].

  89. Matsue Y, Suzuki M, Nishizaki M, Hojo R, Hashimoto Y, Sakurada H. Clinical implications of an implantable cardioverter-defibrillator in patients with vasospastic angina and lethal ventricular arrhythmia. J Am Coll Cardiol. 2012 Sep 4. 60(10):908-13. [Medline].

  90. Klein H, Auricchio A, Reek S, Geller C. New primary prevention trials of sudden cardiac death in patients with left ventricular dysfunction: SCD-HEFT and MADIT-II. Am J Cardiol. 1999 Mar 11. 83(5B):91D-97D. [Medline].

  91. Callaway CW. Epinephrine for cardiac arrest. Curr Opin Cardiol. 2013 Jan. 28(1):36-42. [Medline].

  92. Haïssaguerre M, Shoda M, Jaïs P, Nogami A, Shah DC, Kautzner J, et al. Mapping and ablation of idiopathic ventricular fibrillation. Circulation. 2002 Aug 20. 106(8):962-7. [Medline].

  93. Huang J, Rogers JM, Killingsworth CR, Singh KP, Smith WM, Ideker RE. Evolution of activation patterns during long-duration ventricular fibrillation in dogs. Am J Physiol Heart Circ Physiol. 2004 Mar. 286(3):H1193-200. [Medline].

  94. Kuller LH. Sudden death--definition and epidemiologic considerations. Prog Cardiovasc Dis. 1980 Jul-Aug. 23(1):1-12. [Medline].

  95. Maron BJ, Epstein SE, Roberts WC. Causes of sudden death in competitive athletes. J Am Coll Cardiol. 1986 Jan. 7(1):204-14. [Medline].

  96. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med. 1996 Dec 26. 335(26):1933-40. [Medline].

  97. Murphy JG, Gersh BJ, Mair DD, et al. Long-term outcome in patients undergoing surgical repair of tetralogy of Fallot. N Engl J Med. 1993 Aug 26. 329(9):593-9. [Medline].

  98. Tanno K, Miyoshi F, Watanabe N, Minoura Y, Kawamura M, Ryu S, et al. Are the MADIT II criteria for ICD implantation appropriate for Japanese patients?. Circ J. 2005 Jan. 69(1):19-22. [Medline].

  99. Yoon G, Quitania L, Kramer JH, Fu YH, Miller BL, Ptácek LJ. Andersen-Tawil syndrome: definition of a neurocognitive phenotype. Neurology. 2006 Jun 13. 66(11):1703-10. [Medline].

Epsilon wave on the electrocardiogram of a patient with arrhythmogenic right ventricular dysplasia.
Ventricular fibrillation appeared during rapid atrial fibrillation in a patient with Wolff-Parkinson-White syndrome.
Ventricular fibrillation in a patient with a left ventricular assist device (LVAD).
Table 1. Long QT syndrome diagnostic criteria
Category Criteria Points
Electrocardiographic Findings Corrected QT interval ≥480 ms 3
460-479 ms 2
450-459 ms (in males) 1
Torsade de pointes 2
T wave alternans 1
Notched T waves in three leads 1
Low heart rate for age (resting rate below second percentile 0.5
Clinical History Syncope With stress 2
Without stress 1
Congenital deafness 0.5
Family History Family members with definite long QT syndrome 1
Unexplained SCD before age 30 in immediate family members without definite long QT syndrome 0.5
Adapted from Schwartz PJ, Moss AJ, Vincent GM, Crampton RS. Diagnostic criteria for the long QT syndrome. An update. Circulation. 1993 Aug;88(2):782-4. PMID: 8339437[33]


≤1 point = low probability of long QT syndrome

>1 to 3 points = intermediate probability of long QT syndrome

≥3.5 points = high probability of long QT syndrome

Table 2: Outcome according to initial cardiac arrest score
Cardiac Arrest Score In-hospital mortality rate (%) Neurologic Recovery (%)
0 90 3
1 71 17
2 42 57
3 18 89
Medscape Consult
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.